LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Lannett Co., Inc. (NYSE: LCI), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=LCI. The Company announced on June 26, 2017, that it has received approval from the US Food and Drug Administration of its Abbreviated New Drug Application (ANDA) for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg; the therapeutic equivalent to the reference drug, Norco tablets, 5 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg, of Allergan Pharmaceuticals International Limited. The product is also known under the brand name, Lortab, 5 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on LCI. Go directly to your stock of interest and access today’s free coverage at: http://protraderdaily.com/optin/?symbol=LCI.

Hydrocodone Bitartrate and Acetaminophen Tablets

This drug is administered in the form of a tablet, through an oral intake. Hydrocodone Bitartrate is an opioid analgesic and antitussive and occurs as fine, white crystals or as a crystalline powder. Acetaminophen, on the other hand, is a slightly better, white, odorless, crystalline powder, non-opiate, non-salicylate analgesic and antipyretic.

Effects

Hydrocodone is a semisynthetic narcotic analgesic with multiple actions, similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is still ambiguous, but it is believed to relate to the existence of opiate receptors in the CNS. On the other hand, the analgesic action of acetaminophen involves peripheral influences, with the specific mechanism still undetermined. Acetaminophen inhibits prostaglandin synthetase and has a negligible effect on the cardiovascular and respiratory systems.

Dosage Strength

The dosage strength currently approved by the ANDA represent the primary share of the market for Hydrocodone Bitartrate and Acetaminophen Tablets, and complements the previously approved strengths of 5mg/300 mg, 7.5mg/300 mg, and 10mg/300 mg. Prior to the announcement, on June 22, 2017, the Company announced that it has received an approval from the FDA for its ANDA application concerning Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg, the therapeutic equivalent to the reference standard drug, the Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/300 mg, 7.5 mg/300 mg and 10 mg/300 mg, of Mikart, Inc.

Lannett Growth Prospects

This approval from the FDA, for the Hydrocodone Bitartrate and Acetaminophen Tablets, is viewed as an important and valuable combination drug product for the pain management franchise. The Company received the first approval from the FDA of its ANDA for Butalbital, Acetaminophen, and Caffeine Tablets, USP, 50mg/325mg/40mg, on September 14, 2012, initially, where according to the Company, the sale of these three products, climbed 5% y-o-y for the last three years.

Lannett Co., founded in 1942, deals in development, manufacturing, packaging, marketing, and distribution of generic pharmaceutical products for a wide range of medical indications. Lannett views this approval as a significant milestone, complementary to the two other recently approved ANDAs. The Company expects these approvals to benefit FY18 revenues, while it has 20 more drug applications pending at the FDA, and believe additional approvals will follow this recent announcement.

Last Close Stock Review

On Tuesday, June 27, 2017, the stock closed the trading session at $20.50, marginally down 0.97% from its previous closing price of $20.70. A total volume of 472.95 thousand shares have exchanged hands. Lannett’s stock price advanced 2.24% in the last one month. The stock currently has a market cap of $734.72 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466931

Research Desk Line-up: Actuant Post Earnings Coverage

LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Hebron Technology Co., Ltd (NASDAQ: HEBT), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=HEBT. The Company, which is a developer, manufacturer, and installer of valves and pipe fittings, announced on June 26, 2017, that it has signed a framework cooperation agreement to form a joint venture with Research and Product Complex BioPromin Ltd, a Ukraine-based Company specializing in noninvasive blood analyzing medical devices. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

Discover more of our free reports coverage from other companies within the Diversified Machinery industry. Pro-TD has currently selected Actuant Corporation (NYSE: ATU) for due-diligence and potential coverage as the Company announced on June 21, 2017, its financial results for Q3 which ended on May 31, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Actuant when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HEBT; also brushing on ATU. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=HEBT

http://protraderdaily.com/optin/?symbol=ATU

The Announcement

Subject to the terms of the agreement executed on June 16, 2017, both Hebron and BioPromin have agreed to develop, manufacture, and market BioPromin’s proprietary noninvasive blood analyzing devices in China. The joint venture will be based in Konggang New Area, Longgang District, Wenzhou City, Zhejiang Province, with a registered capital of $5 million and a total investment of up to $50 million. According to the announcement, Hebron will own 80% of the Joint Venture, where BioPromin will hold the remaining 20% of the venture and the right of first refusal to acquire an additional 5% ownership in the venture from Hebron.

Hebron views this agreement as a step to penetrate into the China’s huge medical devices industry. Through the joint venture, the Company plans to integrate deep ties to the pharmaceutical industry and strong capabilities in manufacturing and marketing with BioPromin’s innovative blood analyzing techniques. Hebron plans to bring BioPromin’s clinically-proven blood analyzer products to the Chinese market, through this step.

BioPromin’s portfolio includes products like Automatic Noninvasive Express Screening Analyzer (“ANESA”), Noninvasive Hemogram Analyzer AMP, Low-Intensity Microwave and Decimeter Wave Therapy Apparatus “BIOL”, and Star device.

Hebron Technology

Hebron Technology deals in the development, manufacture, and delivery of customized installation of valves, and pipe fittings. It additionally offers pipeline design, installation, construction, and ongoing maintenance services. For the six month period, ended December 31, 2016, the Company reported that its net revenues surged 17.9% to $16.4 million, with revenues from installation services and fluid equipment sales increasing 19.7% and 5.9% respectively.

Prior to the announcement, on March 10, 2017, the Company announced that it has entered into a non-binding Letter of Intent (LOI) pursuant to which Hebron acquired a majority equity interest in Shanghai Xinxiao Co., Ltd. Xinxiao currently operates one of the largest marketplaces for equipment and products used in the pharmaceutical, biological, chemical, food and beverage, and environmental industries. Hebron viewed this agreement as a definitive plan to expand its ecommerce business while leveraging the extensive database and strong relationships with leading Companies in the particular industry.

On May 24, 2017, Hebron Technology announced that it has won a bid on the design and implementation of an oil-free compressed air pipe project at a pharmaceutical production facility, currently owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. Chase Sun currently operates through its 6,000 employees and reported net annual sales of RMB 3.9 billion. This project was viewed as the development of Company’s pharmaceutical product portfolio, as per the demand pertaining from the leading Pharmaceutical Companies in China. Hebron plans to leverage Chase Sun’s expansion strategy to enhance the scale of its business and establish itself as the leading product manufacturer and deliver in the country.

Last Close Stock Review

At the close of trading session on Tuesday, June 27, 2017, Hebron Technology’s stock price rose 3.91% to end the day at $2.92. A total volume of 33.42 thousand shares were exchanged during the session. The Company’s shares are trading at a PE ratio of 5.92. At Tuesday’s closing price, the stock’s net capitalization stands at $44.03 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466930

Research Desk Line-up: Apogee Enterprises Post Earnings Coverage

LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Martin Marietta Materials, Inc. (NYSE: MLM), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MLM. The Company announced on June 26, 2017, that it is entering into a definitive agreement which pertains to the acquisition of Bluegrass Materials Co. for $1.625 billion in cash. As per Martin Marietta, the transaction will be accretive to earnings per share and cash flow in the first full year. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

Discover more of our free reports coverage from other companies within the General Building Materials industry. Pro-TD has currently selected Apogee Enterprises, Inc. (NASDAQ: APOG) for due-diligence and potential coverage as the Company announced on June 21, 2017, its financial results for Q1 FY18. Tune in to our site to register for a free membership, and be among the early birds that get our report on Apogee Enterprises when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MLM; also brushing on APOG. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=MLM

http://protraderdaily.com/optin/?symbol=APOG

Prospects of the Agreement

This acquisition is set to scale Martin Marietta Materials as a major industry leader and to expand into the mid-Atlantic region. Eventually, Bluegrass’ Georgia and South Carolina operations will accompany Martin Marietta’s existing south-eastern business which will also expand the portfolio of products for new and old customers. It will further simplify Bluegrass Materials Business Model and will maximize shareholder value by focusing on aggregate shipments which are currently 20% to 30% below the peak levels but will benefit from the accelerating economic recovery in the United States.

Bluegrass Materials occupies a leading position in Bowling Green, Eastern Kentucky, and it is also a leading aggregates producer in Maryland, which will provide Martin Marietta with a strategic new growth platform. On completion of the transaction, both companies will work together following their similar culture and values. Additionally, this agreement will help Martin Marietta and Bluegrass achieve growth and operational excellence.

Martin Marietta Growth Profile

Martin Marietta expects to achieve annual run-rate cost savings of about $15 million from this transaction. Including synergies, the purchase price represents a multiple that is in-line with recently completed aggregates transactions.

On July 02, 2014, Martin Marietta Materials announced that it has acquired Texas Industries after the overwhelming response by the shareholders of both companies. This transaction was a result of a special meeting held on June 30, 2014. This enhanced Martin Marietta’s position as a low-cost operator in the US. Along with this acquisition, Martin Marietta gained high-quality assets in cement and ready-mix concrete. Together, Martin Marietta and Texas Industries hold a market capitalization value of approximately $8.8 billion.

Martin Marietta’s New CFO Profile

On June 22, 2017, Martin Marietta Materials announced the retirement of its Executive Vice President and Chief Financial Officer, Anne H. Lloyd, who has been working in this position for 12 years. Anne H. Lloyd will retire in mid-August 2017, but she will be working until September which will allow a smooth transition.

A.J. Nickolas has been selected as the new Senior Vice President and Chief Financial Officer by the Martin Marietta’s Board of Directors. Nickolas will report to C. Howard Nye who is the Chairman, President, and CEO. Nickolas has recently been a major part leading the Corporate Development group at Caterpillar Incorporation and initially served as Group Chief Financial Officer of the Resources Industries segment at Caterpillar.

Bluegrass Materials Working Portfolio

Bluegrass holds a position in the nation’s highest growth markets through its operational investments and also maintains an impressive cost discipline to deliver significant value to shareholders. With an asset portfolio of seven aggregates quarries, three resale aggregates distribution centers, and one concrete block manufacturing facility in Kentucky from CEMEX, Bluegrass has the potential to grow its production base to a large extent with Martin Marietta.

Last Close Stock Review

At the closing bell, on Tuesday, June 27, 2017, Martin Marietta Materials’ stock fell 2.99%, ending the trading session at $225.29. A total volume of 566.90 thousand shares have exchanged hands. The Company’s stock price surged 7.32% in the last three months, 0.08% in the past six months, and 25.69% in the previous twelve months. Moreover, the stock gained 1.70% since the start of the year. The stock is trading at a PE ratio of 34.04 and has a dividend yield of 0.75%. The stock currently has a market cap of $14.15 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466932

LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Moleculin Biotech, Inc. (NASDAQ: MBRX), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MBRX. The Company announced on June 26, 2017, that it has entered into an agreement with a physician at the Mayo Clinic to enable additional research on Moleculin’s WP1066 molecule for the possible treatment of a rare form of pediatric brain tumor. Moleculin is basically a preclinical pharmaceutical Company which excels in the development of anti-cancer drug candidates, where some of them are on behalf of the M.D. Anderson Cancer Center. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MBRX. Go directly to your stock of interest and access today’s free coverage at: http://protraderdaily.com/optin/?symbol=MBRX.

The Announcement

According to the Company, Mayo Clinic physicians and scientists have requested Moleculin to supply them with WP1066 for preclinical testing for the potential treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG), a rare and very aggressive form of brain tumor. According to the Company’s studies, the DIPG may be particularly sensitive to the inhibition of the activated form of a cell-signaling protein called STAT3. The primary target for WP1066 is the cell-signaling protein, called STAT3, where the preliminary studies have demonstrated significant anti-tumor activity of WP1066 in DIPG in-vitro and in-vivo tumor models.

According to multiple Independent research reports, WP1066 is now capable of tumor suppression in xenografts of human brain tumors transplanted into mice. Moleculin stated that it focuses on WP1066, as a potential treatment for DIPG, along with the physician efforts of multiple researchers at the M.D. Anderson Cancer Center, to secure an IND to study and validate the potential importance of WP1066 in the treatment of complicated tumors.

Moleculin Biotech

Moleculin is a preclinical stage pharmaceutical Company aimed at the development of anti-cancer drug candidates, where some of them are derived from M.D. Anderson Cancer Center. The Company’s lead product candidate is Annamycin, an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML). The Company additionally holds two preclinical small molecules under its portfolio, where one of them is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the activation of the patient’s own immune system. On the other hand, the other small molecule portfolio member targets the metabolism of the tumor and prevents its further growth.

On June 15, 2017, the Company announced that it has asked its contract research organization (CRO), Theradex Systems, Inc., to expand its engagement with clinical sites in Poland for the planned Phase-I/II clinical trial of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin stated that in Poland, patients with AML have less access to clinical trials than those in the US. Through this approach, the Company plans to make it easier to recruit an anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia. Moleculin will expand its partnership and engagement with Theradex, and ensure tight coordination of clinical activity between the US and Poland.

Last Close Stock Review

On Tuesday, June 27, 2017, the stock closed the trading session at $1.98, surging 30.26% from its previous closing price of $1.52. A total volume of 25.26 million shares have exchanged hands, which was higher than the 3-month average volume of 664.62 thousand shares. Moleculin Biotech’s stock price skyrocketed 141.46% in the last one month, 76.79% in the past three months, and 1.02% in the previous six months. The stock currently has a market cap of $36.27 million.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466933

LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AMC Entertainment Holdings, Inc. (NYSE: AMC), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=AMC. The Company announced on June 26, 2017, that it has started construction at three ODEON locations in the United Kingdom, on their full-theater renovations, with recliner seating expected to arrive in H2 2017. On average, AMC locations, which have received a similar recliner renovation in the United States, experienced an attendance growth of more than 50% in the first year of operations after the recliners had been installed versus the last twelve months prior to renovations. For immediate access to our complimentary reports, including today’s coverage, register for free now at: http://protraderdaily.com/register/.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on AMC. Go directly to your stock of interest and access today’s free coverage at: http://protraderdaily.com/optin/?symbol=AMC.

The Announcement

AMC announced the commencement of construction at three ODEON locations, namely: ODEON Leeds-Bradford in Bradford, England; ODEON Wester Hailes in Edinburgh, Scotland; and ODEON East Kilbride in Glasgow, Scotland. This announcement comes in the light of AMC’s commitment to deliver an amenity strategy to its ODEON locations, which were acquired at the end of 2016. The Company plans to initiate similar renovation at additional ODEON locations, later in 2017, and accordingly, 25 ODEON theaters are expected to have power-recliner seating by the end of 2018.

All three locations in the UK have been operating for over two decades now, with a lack of significant investment. Post completion of the renovations by the end of 2017, all three theaters will feature 100% plush power recliner seating and ODEON’s full menu of food and beverage offerings.

ODEON’s Acquisition

AMC announced on November 30, 2016, that it has completed the acquisition of the largest theater exhibitor in Europe, namely ODEON & UCI Cinemas Holdings, Ltd from a private equity firm, Terra Firma, for about $1.2 billion. The ODEON portfolio included 244 theaters and 2,243 screens with about 90 million tickets sold annually. Post this acquisition AMC and ODEON together operated 636 theaters with 7,623 screens in eight countries, making it the largest movie exhibition Company in the world.

Company Growth Prospects

AMC is currently the largest movie exhibition Company in the United States, Europe, and throughout the world with a portfolio of about 1,000 theaters and 11,000 screens globally. The Company offers unique and premium services, including latest Hollywood releases and independent programming. Through the ODEON subsidiary, AMC operates in 14 European countries and these three theaters are undergoing renovation from the same portfolio.

On March 28, 2017, AMC announced that it has completed the acquisition of Nordic Cinema Group Holding AB which was the largest theater operator in the Nordic and Baltic countries. AMC paid about $651.9 million in an all-cash transaction, which included a payment of interest on the equity value and repayment of shareholders’ loans. Additionally, AMC repaid the Nordic’s debt of $144.3 million. Post this acquisition, AMC hit the never-before-achieved target of 1,000 theaters and held the market leading position in 9 out of 15 countries of operation.

Last Close Stock Review

On Tuesday, June 27, 2017, the stock closed the trading session at $23.35, slightly falling 0.85% from its previous closing price of $23.55. A total volume of 1.15 million shares have exchanged hands. The stock is trading at a PE ratio of 25.63 and has a dividend yield of 3.43%. The stock currently has a market cap of $3.06 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466941

LONDON, UK / ACCESSWIRE / June 28, 2017 / Pro-Trader Daily takes a closer look at Air Products and Chemicals, Inc. (NYSE: APD) as the Company’s stock will begin trading ex-dividend on June 29, 2017. In order to capture the dividend payout, investors must purchase the stock one day prior to the ex-dividend date that is by latest at the end of trading session on June 28, 2017. Are you looking for research on dividend stocks, if so register with us now for your free membership at: http://protraderdaily.com/register/.

Today, PRO-TD covers ex-dividend news on APD. Get our free coverage by signing up at: http://protraderdaily.com/optin/?symbol=APD.

Dividend Declared

On May 18, 2017, Air Products and Chemicals’ Board of Directors declared a quarterly dividend of $0.95 per share of common stock. The dividend is payable on August 14, 2017, to shareholders of record at the close of business on July 03, 2017.

Air Products’ indicated dividend represents a yield of 2.62% which is higher compared to the average dividend yield for the Basic Materials sector of 2.48%. The Company is a dividend aristocrat and has increased dividend for the past 34 years.

Dividend Insights

Air Products and Chemicals has dividend payout ratio of 61.8% which reflects that the Company distributes approximately $0.62 for every $1.00 earned. The dividend payout ratios reflects how much money a Company is returning to shareholders versus how much money it is keeping on hand to reinvest in growth, pay off debt, and/or add to cash reserves.

According to analysts’ estimates, Air Products and Chemicals is expected to report earnings of $6.79 in the coming year, which again substantially covers the Company’s annualized dividend of $3.80.

As on March 31, 2017, Air Products and Chemicals had cash and cash items worth $1.87 billion and its current assets totaled $5.30 billion, while current liabilities were in the sum of $2.60 billion. The strong financial position would allow the Company to absorb any fluctuations in earnings and pay its dividend without interruption.

About the Company

Air Products and Chemicals is a world-leading industrial gases company which has been in operation for over 75 years. The Company’s core industrial gases business provides atmospheric and process gases and related equipment to manufacturing markets, including refining and petrochemical, metals, electronics, and food and beverage. Air Products and Chemicals is also the world’s leading supplier of liquefied natural gas process technology and equipment.

The Company had fiscal 2016 sales of $7.5 billion from continuing operations in 50 countries and has a current market capitalization of approximately $31.34 billion.

Recent Development for Air Products

On June 15, 2017, Air Products and Chemicals announced it has formed a new joint venture with Linde North America named East Coast Nitrogen and will build a new 1,100 ton per day world-scale air separation unit and industrial gas liquefier in Glenmont, New York. An approximate capital investment of $60 million will be made in the new facility which will produce liquid nitrogen, liquid oxygen, and liquid argon. The new plant will be constructed and operated by Air Products and Chemicals with commercial status targeted for December 2018.

Stock Performance

On Tuesday, June 27, 2017, the stock closed the trading session at $143.83, slightly down 0.75% from its previous closing price of $144.91. A total volume of 796.57 thousand shares have exchanged hands. Air Products and Chemicals’ stock price surged 4.79% in the past three months, and 15.39% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have gained 0.01%. The stock is trading at a PE ratio of 24.00 and has a dividend yield of 2.64%. The stock currently has a market cap of $31.34 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 466940